D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $9.00 target price on the stock.

A number of other research firms also recently weighed in on IVVD. HC Wainwright reduced their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Morgan Stanley reduced their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $7.89.

Invivyd Trading Up 17.9 %

Shares of IVVD opened at $1.25 on Monday. Invivyd has a 1-year low of $0.35 and a 1-year high of $5.10. The firm’s 50-day moving average price is $0.51 and its 200-day moving average price is $0.82. The firm has a market capitalization of $149.53 million, a price-to-earnings ratio of -0.64 and a beta of 0.61.

Insider Activity at Invivyd

In other news, Director Terrance Mcguire sold 160,400 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at approximately $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 816,466 shares of company stock valued at $423,214 in the last 90 days. Corporate insiders own 17.90% of the company’s stock.

Hedge Funds Weigh In On Invivyd

A number of hedge funds have recently bought and sold shares of IVVD. State Street Corp raised its holdings in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after buying an additional 35,904 shares during the last quarter. Marshall Wace LLP lifted its position in Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after acquiring an additional 31,992 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Invivyd during the 2nd quarter valued at $421,000. Cubist Systematic Strategies LLC increased its holdings in shares of Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after purchasing an additional 53,499 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after purchasing an additional 75,780 shares in the last quarter. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.